Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Bevacizumab and Verteporfin (Standard and Reduced Fluence)in the Treatment of Neovascular Age-Related Macular Degeneration

NCT00729846 is registered in ClinicalTrials.gov with California Retina Consultants as lead sponsor.

NCT NCT00729846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00729846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Bevacizumab and Verteporfin (Standard and Reduced Fluence)in the Treatment of Neovascular Age-Related Macular Degeneration
Lead sponsor
California Retina Consultants
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
July 31, 2009
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration, choroidal neovascularization, macular edema